Ikena Oncology has been granted a patent for compounds and methods for treating cancer. The invention includes specific compounds and compositions for use in treating cancer patients. GlobalData’s report on Ikena Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ikena Oncology Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ikena Oncology, Cancer treatment biomarkers was a key innovation area identified from patents. Ikena Oncology's grant share as of February 2024 was 10%. Grant share is based on the ratio of number of grants to total number of patents.

Cancer treatment method using compounds of formula i

Source: United States Patent and Trademark Office (USPTO). Credit: Ikena Oncology Inc

A recently granted patent (Publication Number: US11925651B2) discloses a method for treating cancer in a patient by administering a compound of Formula I'. The method involves specific criteria such as the structure of the compound, including the bivalent hydrocarbon chain L1, the phenyl ring A, and the heterocyclic ring Y, among others. The patent outlines various specific compounds falling under Formulas IX, X, XII, XIII, XIV, and XV, each with distinct structural features that are crucial for their efficacy in treating cancer.

Furthermore, the patent specifies that the cancer to be treated should be associated with increased TEAD expression or activity, particularly TEAD1, TEAD2, TEAD3, or TEAD4. Additionally, the method is particularly effective for cancers where YAP is localized in the nucleus of cancer cells. The patent lists various types of cancers that can be treated using this method, including lung cancer, thyroid cancer, ovarian cancer, colorectal cancer, prostate cancer, pancreatic cancer, esophageal cancer, liver cancer, breast cancer, skin cancer, mesothelioma, or leukemia. Overall, the patent provides a detailed and structured approach to treating cancer using specific compounds and targeting cancer types with increased TEAD expression or activity, offering a promising avenue for cancer treatment research and development.

To know more about GlobalData’s detailed insights on Ikena Oncology, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies